奥扎格雷联合依达拉奉治疗急性脑梗死的效果
摘要：目的 觀察奥扎格雷联合依达拉奉治疗急性脑梗死的效果。方法 选择2018年5月～2019年5月在我院诊治的急性脑梗死患者106例，采用随机数字表法分为对照组和观察组，各53例。对照组采用奥扎格雷治疗，观察组在对照组基础上联合依达拉奉治疗，比较两组临床治疗总有效率、治疗前后神经功能缺损评分(NIHSS)和日常生活能力评分(Barthel)、临床不良反应。结果 观察组治疗总有效率为94.33%，高于对照组的81.13%，差异有统计学意义(P<0.05);治疗后两组NIHSS评分均低于治疗前，且观察组低于对照组，差异有统计学意义(P<0.05);治疗后两组Barthel评分均高于治疗前，且观察组高于对照组，差异有统计学意义(P<0.05);观察组临床不良反应率为5.66%，与对照组的7.54%比较，差异无统计学意义(P>0.05)。结论 奥扎格雷联合依达拉奉治疗急性脑梗死效果确切，有助于改善神经功能，提高患者日常生活能力，同时临床不良反应小，联合用药方案安全可行，值得临床应用。
关键词：奥扎格雷;依达拉奉;急性脑梗死
中图分类号：R743.33 文献标识码：A DOI：10.3969/j.issn.1006-1959.2020.01.044
文章编号：1006-1959(2020)01-0140-02
Effect of Ozagrel Combined with Edaravone on Acute Cerebral Infarction
CAO Jin-qiang，MAO Shi-ming，WANG Wan-guo
(Department of Neurology，Zhijiang People's Hospital，Zhijiang 443200，Hubei，China)
Abstract：Objective To observe the effect of ozagrel combined with edaravone on acute cerebral infarction. Methods A total of 106 patients with acute cerebral infarction diagnosed and treated in our hospital from May 2018 to May 2019 were selected and randomly divided into a control group and an observation group， with 53 cases in each group. The control group was treated with ozagrel， and the observation group was combined with edaravone treatment on the basis of the control group. The total effective rate of clinical treatment， neurological deficit score (NIHSS)， daily life ability score (Barthel)， and clinical adverse reactions were compared between the two groups.Results The total effective rate of treatment in the observation group was 94.33%， which was higher than 81.13% in the control group，the difference was statistically significant (P<0.05). After treatment， the NIHSS scores of the two groups were lower than before the treatment， and the observation group was lower than the control group，the difference wasstatistically significant (P<0.05); the Barthel scores of the two groups after treatment were higher than before the treatment， and the observation group was higher than the control group， the difference was statistically significant (P<0.05); the clinical adverse reaction rate of the observation group was 5.66% compared with 7.54% of the control group， the difference was not statistically significant (P>0.05).Conclusion Ozagrel combined with edaravone is effective in the treatment of acute cerebral infarction， which is helpful to improve neurological function and improve the daily living ability of patients. At the same time， the clinical adverse reactions are small， and the combined drug regimen is safe and feasible， which is worthy of clinical application., 百拇医药(曹金强 毛士明 汪万国)
关键词：奥扎格雷;依达拉奉;急性脑梗死
中图分类号：R743.33 文献标识码：A DOI：10.3969/j.issn.1006-1959.2020.01.044
文章编号：1006-1959(2020)01-0140-02
Effect of Ozagrel Combined with Edaravone on Acute Cerebral Infarction
CAO Jin-qiang，MAO Shi-ming，WANG Wan-guo
(Department of Neurology，Zhijiang People's Hospital，Zhijiang 443200，Hubei，China)
Abstract：Objective To observe the effect of ozagrel combined with edaravone on acute cerebral infarction. Methods A total of 106 patients with acute cerebral infarction diagnosed and treated in our hospital from May 2018 to May 2019 were selected and randomly divided into a control group and an observation group， with 53 cases in each group. The control group was treated with ozagrel， and the observation group was combined with edaravone treatment on the basis of the control group. The total effective rate of clinical treatment， neurological deficit score (NIHSS)， daily life ability score (Barthel)， and clinical adverse reactions were compared between the two groups.Results The total effective rate of treatment in the observation group was 94.33%， which was higher than 81.13% in the control group，the difference was statistically significant (P<0.05). After treatment， the NIHSS scores of the two groups were lower than before the treatment， and the observation group was lower than the control group，the difference wasstatistically significant (P<0.05); the Barthel scores of the two groups after treatment were higher than before the treatment， and the observation group was higher than the control group， the difference was statistically significant (P<0.05); the clinical adverse reaction rate of the observation group was 5.66% compared with 7.54% of the control group， the difference was not statistically significant (P>0.05).Conclusion Ozagrel combined with edaravone is effective in the treatment of acute cerebral infarction， which is helpful to improve neurological function and improve the daily living ability of patients. At the same time， the clinical adverse reactions are small， and the combined drug regimen is safe and feasible， which is worthy of clinical application., 百拇医药(曹金强 毛士明 汪万国)